Clinical Trials Logo

Clinical Trial Summary

Acinetobacter baumannii causes severe infections (pneumonia, bacteremia, organ space) with high lethality in hospitalised critically ill patients. It can acquire resistance to all classes of antibiotics (multidrug resistance, MDR) except an 'old' drug, colistin, which may be the only therapeutic option. The addition of minocycline to colistin has been shown to be synergistic in vitro, and may be promising in vivo, but this combination has not been limited to case report or case series in comparison with colistin alone.


Clinical Trial Description

The purpose of this double-blind, randomized, parallel, placebo-controlled clinical trial is to assess whether the association of colistin and minocycline reduces significantly the mortality of patients with severe MDR A. baumannii infections compared with colistin alone. The trial will enroll 94 patients from internal medicine ward and intensive care units (ICU) of an university care hospitals where MDR A. baumannii infection is endemic with epidemic phases. Patients will be randomly allocated to either colistin plus placebo (control arm) or colistin plus minocycline (experimental arm). Primary end point is overall mortality, defined as death occurring within 28 days from randomisation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05586815
Study type Interventional
Source Mahidol University
Contact Adhiratha Boonyasiri, MD
Phone +66850632181
Email adhiratha.bon@mahidol.ac.th
Status Recruiting
Phase Phase 4
Start date January 10, 2023
Completion date June 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT02688322 - Pharmacodynamics Modeling to Optimize Dosage Regimens of Sulbactam in Patients With Acinetobacter Infections Phase 4
Completed NCT03622918 - Colistin-rifampin Combination and Colistin Monotherapy in Extensively Drug-resistant Acinetobacter Baumannii N/A
Enrolling by invitation NCT05880069 - Clinical Outcomes in Patients With Infection by Resistant Microorganism
Completed NCT02482961 - Impact of Plasma Levels of Colistin in Patients With Carbapenem Resistant Acinetobacter Baumannii Infection
Completed NCT00524563 - Clinical Outcomes and Global Epidemiology -Data Coordinating Center
Terminated NCT05210387 - Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections N/A
Completed NCT02573064 - Impact of Treatment With Colistin on Mortality Bacteremia Multiresistant Acinetobacter Baumannii Sensitive Colistin in Patients Critical N/A
Completed NCT00524290 - Multinational Study of Acinetobacter Bloodstream Infection: Clinical Outcomes and Global Epidemiology-PITT Protocol
Completed NCT00462579 - Risk Factors for Carbapenem-resistant Acinetobacter Baumannii